

# Interrupted Time Series (ITS) in Big Data Research

Chengsheng Ju, PhD student

# A brief introduction


- Useful for evaluation of public health interventions at a population-level
- E.g. \_\_\_\_\_

Suicide trends in the early months of the COVID-19 pandemic: an interrupted time-series analysis of preliminary data from 21 countries



- ITS - a time series that is 'interrupted' by an intervention
- Compare pre-intervention and post-intervention measurements
- A quasi-experimental design for observational data

# ITS Analysis with segmented linear regression



Standard linear regression:

$$Y = \beta_0 + \beta_1 X$$


Segmented linear regression:

$$Y_t = \beta_0 + \beta_1 X + \beta_2 T + \beta_3 TX_t$$

| X   | Y   | T   | X <sub>t</sub> |
|-----|-----|-----|----------------|
| 1   | 100 | 0   | 0              |
| 2   | 105 | 0   | 0              |
| 3   | 110 | 0   | 0              |
| 4   | 115 | 0   | 0              |
| 5   | 120 | 0   | 0              |
| 6   | 125 | 0   | 0              |
| 7   | 130 | 0   | 0              |
| 8   | 135 | 0   | 0              |
| 9   | 140 | 0   | 0              |
| 10  | 145 | 0   | 0              |
| 11  | 150 | 0   | 0              |
| 12  | 155 | 0   | 0              |
| 13  | 180 | 1   | 1              |
| 14  | 190 | 1   | 2              |
| 15  | 200 | 1   | 3              |
| 16  | 210 | 1   | 4              |
| 17  | 220 | 1   | 5              |
| 18  | 230 | 1   | 6              |
| ... | ... | ... | ...            |

# ITS Analysis – other considerations

- Other impact models
- Autocorrelation and seasonality
- Controls series/ effect modifiers/ sample size?








# Example

Open access

Original research

## BMJ Open Changes in prescribing rates of sodium-containing medications in the UK from 2009 to 2018: a cross-sectional study with interrupted time series analysis

Chengsheng Ju <sup>1</sup>, Li Wei <sup>1</sup>, Isla S Mackenzie <sup>2</sup>, Thomas M MacDonald <sup>2</sup>,  
Jacob George <sup>2</sup>

<http://dx.doi.org/10.1136/bmjopen-2020-043566>


# Example – descriptive

## Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case-control study




OPEN ACCESS

BMJ 2013;347:f6954 doi: 10.1136/bmj.f6954 (Published 26 November 2013)



A



B

# Example – ITSA with control

|                              | Baseline level (95% CI) | Baseline slope (95% CI) | Change in level (95% CI) | P value | Change in slope (95% CI) | P value      |
|------------------------------|-------------------------|-------------------------|--------------------------|---------|--------------------------|--------------|
| Prescribing rate             |                         |                         |                          |         |                          |              |
| Sodium overall               | 69.2 (65.9 to 72.5)     | 0.03 (–0.13 to 0.18)    | 0.59 (–2.19 to 3.37)     | 0.678   | –0.26 (–0.45 to –0.07)   | <b>0.009</b> |
| Non-sodium overall (control) | 765.1 (728.8 to 801.3)  | 1.58 (–0.08 to 3.24)    | 22.3 (–8.14 to 52.7)     | 0.151   | 1.14 (–0.99 to 3.27)     | 0.294        |

| Change in level (95% CI) | P value |
|--------------------------|---------|
| 0.59 (–2.19 to 3.37)     | 0.678   |
| 22.3 (–8.14 to 52.7)     | 0.151   |

| Change in slope (95% CI) | P value      |
|--------------------------|--------------|
| –0.26 (–0.45 to –0.07)   | <b>0.009</b> |
| 1.14 (–0.99 to 3.27)     | 0.294        |

# Example – effect modifier

|                   | Baseline level (95% CI) | Baseline slope (95% CI) | Change in level (95% CI) | P value | Change in slope (95% CI) | P value          |
|-------------------|-------------------------|-------------------------|--------------------------|---------|--------------------------|------------------|
| sex               |                         |                         |                          |         |                          |                  |
| Sodium user man   | 39.10 (37.61 to 40.59)  | 0.04 (–0.02 to 0.11)    | 0.36 (–0.94 to 1.65)     | 0.590   | –0.16 (–0.26 to –0.09)   | <b>&lt;0.001</b> |
| Sodium user woman | 73.38 (70.51 to 76.25)  | 0.01 (–0.01 to 0.01)    | 0.77 (–1.64 to 3.18)     | 0.532   | –0.27 (–0.44 to –0.10)   | <b>0.002</b>     |

|                             |                           |                       |                       |       |                        |                  |
|-----------------------------|---------------------------|-----------------------|-----------------------|-------|------------------------|------------------|
| age                         |                           |                       |                       |       |                        |                  |
| Sodium user age <45 years   | 12.96 (12.29 to 13.63)    | –0.03 (–0.06 to 0.00) | 0.23 (–0.35 to 0.81)  | 0.439 | –0.03 (–0.07 to 0.01)  | 0.113            |
| Sodium user age 45–54 years | 43.77 (42.03 to 45.51)    | 0.04 (–0.04 to 0.11)  | –0.17 (–1.71 to 1.38) | 0.833 | –0.12 (–0.22 to –0.02) | <b>0.020</b>     |
| Sodium user age 55–64 years | 81.07 (78.21 to 83.92)    | –0.07 (–0.19 to 0.06) | –0.41 (–2.95 to 2.14) | 0.754 | –0.21 (–0.38 to –0.05) | <b>0.011</b>     |
| Sodium user age 65–74 years | 128.34 (123.23 to 133.46) | 0.30 (0.07 to 0.53)   | –2.28 (–6.72 to 2.16) | 0.314 | –0.68 (–0.98 to –0.39) | <b>&lt;0.001</b> |
| Sodium user age 74–84 years | 226.90 (219.18 to 234.62) | –0.05 (–0.40 to 0.30) | 3.18 (–3.52 to 9.87)  | 0.352 | –0.71 (–1.15 to –0.26) | <b>0.002</b>     |
| Sodium user age ≥85 years   | 304.96 (293.46 to 316.46) | –0.37 (–0.88 to 0.13) | 9.45 (–0.78 to 19.69) | 0.070 | –0.69 (–1.35 to –0.03) | <b>0.041</b>     |



# Assumptions and limitations

- Pre-intervention trends are assumed to be linear
- The characteristics of the populations remain unchanged throughout the study period
- No background interventions during the study period